AIN457 + AIN 457 + AIN457
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-infectious Uveitis
Conditions
Non-infectious Uveitis
Trial Timeline
Jun 1, 2008 → Sep 1, 2013
NCT ID
NCT00685399About AIN457 + AIN 457 + AIN457
AIN457 + AIN 457 + AIN457 is a phase 2 stage product being developed by Novartis for Non-infectious Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00685399. Target conditions include Non-infectious Uveitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00685399 | Phase 2 | Completed |
Competing Products
10 competing products in Non-infectious Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Adalimumab | AbbVie | Approved | 85 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 52 |
| AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| ESK-001 | Alumis | Phase 2 | 47 |
| Topical Prednisolone Acetate 1% | Ocular Therapeutix | Approved | 80 |
| FAI insert + Sham injection | EyePoint Pharmaceuticals | Phase 3 | 72 |
| FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserter | EyePoint Pharmaceuticals | Phase 3 | 72 |
| ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution | Aldeyra Therapeutics | Phase 3 | 69 |
| NS2 + Prednisolone acetate ophthalmic suspension (1%) | Aldeyra Therapeutics | Phase 2 | 44 |